AstraZeneca’s reiteration of its previously announced freeze on investments in U.K. manufacturing has caused alarm among politicians. In the fevered pre-Brexit environment, pro-Remain politicians saw the reiteration of an old position as evidence the split from the U.K. will decimate life science research.
The excitement stems from a comment AstraZeneca chairman Leif Johansson made to French newspaper Le Monde. Johansson said AstraZeneca would maintain its decision not to invest in the U.K. if there is no transition deal that clarifies the terms of the post-Brexit relationship with the European Union. The comment was seized upon by politicians opposed to Brexit.
“More grim #BrexitReality as AstraZeneca halts investment in U.K. No one voted to decimate medical research,” Sarah Wollaston, a pro-Remain MP, doctor and chair of the Health and Social Care Select Committee, wrote on Twitter.
Wollaston was not the only public figure to see implications for U.K. life science research in Johansson’s comments. Phillip Lee, a politician who resigned over the government’s approach to Brexit, made a similar link to Wollaston, stating “we need to keep our world-class research base if we want our pharmaceutical industry to survive and thrive.”
The fears are somewhat divorced from the current reality, though. While certain outcomes to Brexit could feasibly affect AstraZeneca’s investment in R&D in the U.K., as it stands the company is pushing ahead with its projects.
“Things are as they were nearly 18 months ago,” a spokesperson for AstraZeneca said. “The freeze is on the manufacturing side. The Cambridge stuff, the R&D, that’s unchanged.”
While Johansson’s comments were seen as a bombshell in some quarters, they are a continuation of a position AstraZeneca adopted last year. Back then, CEO Pascal Soriot told the Financial Times AstraZeneca was holding off on new investments in U.K. manufacturing until there was clarity over the future regulatory regime and relationship to the EU.
By Nick Paul Taylor
Source: Fierce Biotech
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
